生物活性 | |||
---|---|---|---|
描述 | Sofpironium bromide, also known as BBI 4000, is an anticholinergic drug used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high affinity for the M1, M2, M4, and M5 isoforms. Sofpironium bromide is metabolised primarily by non-enzymatic hydrolysis, but also oxidatively by CYP2D6 and CYP3A4. Sofpironium bromide has anticholinergic activity and inhibits the activity of guinea pig ileal tissue in a concentration-dependent manner. Sofpironium bromide has anticholinergic activity and inhibits the contractile activity of guinea pig ileum tissue in a concentration-dependent manner. In a rat model, Sofpironium bromide reduced footpad sweating induced by pilocarpine, a muscarinic receptor agonist[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.13mL 0.43mL 0.21mL |
10.63mL 2.13mL 1.06mL |
21.26mL 4.25mL 2.13mL |
参考文献 |
---|
[1]Julia Paik, et al. Sofpironium Bromide: First Approval. Drugs. 2020 Dec;80(18):1981-1986. |